Focus:
News
-
10 July 2020
Approved COVID-19 vaccine could be available in six months; high-risk groups should get priority access: Poll
The global spread of the COVID-19 pandemic and the resulting economic impact and public health burden has highlighted the urgent need for a vaccine to prevent the disease
-
10 July 2020
AIM ImmunoTech to study Ampligen in Covid-19 patients with cancer
AIM ImmunoTech has signed a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center for a Phase I/IIa clinical trial of Ampligen (rintatolimod) in combination with interferon alfa-2b for...
-
10 July 2020
Enanta advances HBV candidate EDP-514 in Phase I trials
Enanta Pharmaceuticals has launched a Phase Ib clinical trial of EDP-514, a hepatitis B virus (HBV) core inhibitor, in viremic HBV patients.
-
9 July 2020
NIH launches trials network for Covid-19 vaccines and therapies
The US National Institutes of Health (NIH)'s National Institute of Allergy and Infectious Diseases (NIAID) has launched a new clinical trials network for testing potential vaccines and monoclonal antibodies against...
-
9 July 2020
Gilead begins testing of inhaled version of remdesivir for Covid-19
Gilead Sciences has launched a Phase Ia clinical trial of an inhaled version of remdesivir to treat Covid-19 patients in the outpatient setting.
-
9 July 2020
Moderna closes enrolment in Phase II Covid-19 vaccine study
Biotechnology firm Moderna has concluded participant enrolment for both cohorts in the Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273.
-
8 July 2020
University of Oxford selects eClinical suite for Covid-19 trial
Unified eClinical solutions provider Axiom Real-Time Metrics has announced its partnership with the University of Oxford for its clinical trial focused on the preventative treatments of Covid-19.
-
8 July 2020
ViiV’s long-acting cabotegravir outperforms daily pill in HIV trial
ViiV Healthcare has reported that its long-acting, injectable cabotegravir given every two months showed superior efficacy over Gilead Sciences' daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to prevent HIV.
-
8 July 2020
Biophytis and SGS partner to test Sarconeos in Covid-19 patients
French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
-
8 July 2020
Corvus starts Phase I trial of immunotherapy to treat Covid-19
Corvus Pharmaceuticals has launched a Phase I clinical trial of its new immunotherapy product, CPI-006, for the treatment of patients with Covid-19.